15 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Constraining the amide bond in N-sulfonylated dipeptide VLA-4 antagonists.
Merck Research Laboratories
Synthesis and biological activity of N-substituted aminocarbonyl-1,3-dioxolanes as VLA-4 antagonists.
New Drug Discovery Research
Heterocycle-substituted proline dipeptides as potent VLA-4 antagonists.
Merck Research Laboratories
Discovery of N-{N-[(3-cyanophenyl)sulfonyl]-4(R)-cyclobutylamino-(L)-prolyl}-4-[(3',5'-dichloroisonicotinoyl) amino]-(L)-phenylalanine (MK-0668), an extremely potent and orally active antagonist of very late antigen-4.
Merck Research Laboratories
A novel and potent VLA-4 antagonist based on trans-4-substituted cyclohexanecarboxylic acid.
Daiichi Sankyo
Selectively targeting T- and B-cell lymphomas: a benzothiazole antagonist of alpha4beta1 integrin.
University of California Davis
Identification of 4-[1-[3-chloro-4-[N'-(5-fluoro-2-methylphenyl)ureido]phenylacetyl]-(4S)-fluoro-(2S)-pyrrolidinylmethoxy]benzoic acid as a potent, orally active VLA-4 antagonist.
Daiichi Sankyo
Synthetic study of VLA-4/VCAM-1 inhibitors: synthesis and structure-activity relationship of piperazinylphenylalanine derivatives.
Kyowa Hakko Kogyo
The design and synthesis of potent cyclic peptide VCAM-VLA-4 antagonists incorporating an achiral Asp-Pro mimetic.
Roche Research Center
Isoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
Merck Sharpe & Dohme
A highly potent non-nucleoside adenosine deaminase inhibitor: efficient drug discovery by intentional lead hybridization.
Fujisawa Pharmaceutical